Compare · BNTX vs VCKA
BNTX vs VCKA
Side-by-side comparison of BioNTech SE (BNTX) and Vickers Vantage Corp. I (VCKA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BNTX and VCKA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- BNTX is the larger of the two at $24.29B, about 139.5x VCKA ($174.1M).
- BNTX has hit the wire 12 times in the past 4 weeks while VCKA has been quiet.
- BNTX has more recent analyst coverage (25 ratings vs 0 for VCKA).
- Company
- BioNTech SE
- Vickers Vantage Corp. I
- Price
- $95.82-0.83%
- $8.51-15.74%
- Market cap
- $24.29B
- $174.1M
- 1M return
- +4.60%
- -
- 1Y return
- -3.46%
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- 2021
- News (4w)
- 12
- 0
- Recent ratings
- 25
- 0
BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody, which is in Phase I/IIa clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
Vickers Vantage Corp. I
Vickers Vantage Corp. I does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2020 and is based in Singapore.
Latest BNTX
- A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat
- Chief Executive Officer Sahin Ugur sold $8,439,336 worth of Ordinary Shares (86,000 units at $98.13) as part of a pre-agreed trading plan, decreasing direct ownership by 12% to 602,209 units (SEC Form 4)
- SEC Form 6-K filed by BioNTech SE
- BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients
- Chief Executive Officer Sahin Ugur sold $1,974,287 worth of Ordinary Shares (20,500 units at $96.31) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 688,209 units (SEC Form 4)
- Chief Executive Officer Sahin Ugur sold $7,190,663 worth of Ordinary Shares (73,000 units at $98.50) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 708,709 units (SEC Form 4)
- Chief Executive Officer Sahin Ugur sold $7,889,055 worth of Ordinary Shares (76,500 units at $103.12) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 781,709 units (SEC Form 4)
- BioNTech downgraded by BMO Capital Markets with a new price target
- SEC Form 6-K filed by BioNTech SE
- SEC Form 6-K filed by BioNTech SE
Latest VCKA
- SEC Form 8-K filed by Vickers Vantage Corp. I
- SEC Form SC 13D/A filed by Vickers Vantage Corp. I (Amendment)
- SEC Form EFFECT filed by Vickers Vantage Corp. I
- SEC Form 424B5 filed by Vickers Vantage Corp. I
- SEC Form S-3/A filed by Vickers Vantage Corp. I (Amendment)
- Vickers Vantage Corp. I filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 424B3 filed by Vickers Vantage Corp. I
- SEC Form 424B3 filed by Vickers Vantage Corp. I
- SEC Form 424B3 filed by Vickers Vantage Corp. I
- SEC Form 424B3 filed by Vickers Vantage Corp. I